Cargando…

SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and...

Descripción completa

Detalles Bibliográficos
Autores principales: Walls, Alexandra C., Sprouse, Kaitlin R., Bowen, John E., Joshi, Anshu, Franko, Nicholas, Navarro, Mary Jane, Stewart, Cameron, Cameroni, Elisabetta, McCallum, Matthew, Goecker, Erin A., Degli-Angeli, Emily J., Logue, Jenni, Greninger, Alex, Corti, Davide, Chu, Helen Y., Veesler, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769922/
https://www.ncbi.nlm.nih.gov/pubmed/35123650
http://dx.doi.org/10.1016/j.cell.2022.01.011
_version_ 1784635250687606784
author Walls, Alexandra C.
Sprouse, Kaitlin R.
Bowen, John E.
Joshi, Anshu
Franko, Nicholas
Navarro, Mary Jane
Stewart, Cameron
Cameroni, Elisabetta
McCallum, Matthew
Goecker, Erin A.
Degli-Angeli, Emily J.
Logue, Jenni
Greninger, Alex
Corti, Davide
Chu, Helen Y.
Veesler, David
author_facet Walls, Alexandra C.
Sprouse, Kaitlin R.
Bowen, John E.
Joshi, Anshu
Franko, Nicholas
Navarro, Mary Jane
Stewart, Cameron
Cameroni, Elisabetta
McCallum, Matthew
Goecker, Erin A.
Degli-Angeli, Emily J.
Logue, Jenni
Greninger, Alex
Corti, Davide
Chu, Helen Y.
Veesler, David
author_sort Walls, Alexandra C.
collection PubMed
description Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and -neutralizing antibody responses that are markedly more potent, durable, and resilient to spike mutations observed in variants than those in subjects who received only 2 doses of vaccine. However, we show that breakthrough cases, subjects who were vaccinated after infection, and individuals vaccinated three times have serum-neutralizing activity of comparable magnitude and breadth, indicating that an increased number of exposures to SARS-CoV-2 antigen(s) enhance the quality of antibody responses. Neutralization of SARS-CoV was moderate, however, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness.
format Online
Article
Text
id pubmed-8769922
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-87699222022-01-20 SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses Walls, Alexandra C. Sprouse, Kaitlin R. Bowen, John E. Joshi, Anshu Franko, Nicholas Navarro, Mary Jane Stewart, Cameron Cameroni, Elisabetta McCallum, Matthew Goecker, Erin A. Degli-Angeli, Emily J. Logue, Jenni Greninger, Alex Corti, Davide Chu, Helen Y. Veesler, David Cell Article Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and -neutralizing antibody responses that are markedly more potent, durable, and resilient to spike mutations observed in variants than those in subjects who received only 2 doses of vaccine. However, we show that breakthrough cases, subjects who were vaccinated after infection, and individuals vaccinated three times have serum-neutralizing activity of comparable magnitude and breadth, indicating that an increased number of exposures to SARS-CoV-2 antigen(s) enhance the quality of antibody responses. Neutralization of SARS-CoV was moderate, however, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness. Elsevier Inc. 2022-03-03 2022-01-20 /pmc/articles/PMC8769922/ /pubmed/35123650 http://dx.doi.org/10.1016/j.cell.2022.01.011 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Walls, Alexandra C.
Sprouse, Kaitlin R.
Bowen, John E.
Joshi, Anshu
Franko, Nicholas
Navarro, Mary Jane
Stewart, Cameron
Cameroni, Elisabetta
McCallum, Matthew
Goecker, Erin A.
Degli-Angeli, Emily J.
Logue, Jenni
Greninger, Alex
Corti, Davide
Chu, Helen Y.
Veesler, David
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
title SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
title_full SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
title_fullStr SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
title_full_unstemmed SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
title_short SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
title_sort sars-cov-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769922/
https://www.ncbi.nlm.nih.gov/pubmed/35123650
http://dx.doi.org/10.1016/j.cell.2022.01.011
work_keys_str_mv AT wallsalexandrac sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT sprousekaitlinr sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT bowenjohne sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT joshianshu sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT frankonicholas sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT navarromaryjane sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT stewartcameron sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT cameronielisabetta sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT mccallummatthew sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT goeckererina sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT degliangeliemilyj sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT loguejenni sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT greningeralex sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT cortidavide sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT chuheleny sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses
AT veeslerdavid sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses